JPRN-UMIN000010090已完成1 期
Phase I study of Erlotinib and Crizotinib after ALK inhibitor failure in ALK positive advanced Non-Small Cell Lung Cancer - Phase I study of Erlotinib and Crizotinib after ALK inhibitor failure in ALK positive advanced Non-Small Cell Lung Cancer
Medical thoracic oncology, Cancer institute hospital, Japanese Foundation For Cancer Reseach0 个研究点目标入组 30 人开始时间: 2013年2月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)No prior treatment with EGFR-TKI 2)Patients with uncontrollable complications(e.g. uncontrollable heart disease, severe arrhythmia, continuous diarrhea). 3)Patients with active severe brain metastasis. 4)1)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 5)History of active double cancer within 5 years prior to the study. 6)Patients with symptomatic brain metastasis 7)Impossible cases with oral administration. 8)Pregnancy or lactation 9) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
研究者
相似试验
已完成
2 期
A phase II study of Erlotinib for patients previously treated non-small cell lung cancer with epidermal growth factor receptor mutationon-small cell lung cancerJPRN-UMIN000004563Fukushima Medical University, cancer center26
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
招募中
2 期
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27
已完成
不适用
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40